PhRMA @ #ASCO13: Biopharmaceutical Sector Propels Economic Activity

PhRMA @ #ASCO13: Biopharmaceutical Sector Propels Economic Activity

06.01.13 | By

The Catalyst is covering #ASCO13 this weekend and we’ll be posting ongoing thoughts on the pulse of the conference. We welcome your feedback and encourage you to leave comments below or tweet @PhRMA.   

As more than 25,000 oncology professionals meet for ASCO’s annual meeting, it’s clear that the U.S. has a unique advantage when it comes to biopharmaceutical innovation. Patients greatly benefit from the innovative treatments developed domestically, and with improved health and medical innovation contributing to more than half of our economic growth, the biopharmaceutical sector should be considered an important economic driver. The U.S. ranks first in life sciences employment, with biopharmaceutical research companies alone support nearly four million jobs.

As the U.S. economy continues to rebound from the recent economic downturn, continuing to advance biomedical research and innovation will be key. Since 2000, PhRMA member companies have invested nearly $550 billion in researching and developing life-enhancing medicines. This not only benefits patients, but also propels our economy. Show your support for the job creators in our industry by sharing a comment, or tweeting at us @PhRMA.



Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context